All In Biotech

Drug Trial Radar · NCT03388125

Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection

Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices

Last checked: Nov 20, 2026Latest source record: Apr 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 113 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

113

Actual

Start

Jan 1, 2016

Primary completion

Aug 1, 2017

Study completion Dec 1, 2022

Sponsor

Lead sponsor
Sherief Abd-ElsalamAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Endoscopic Injection Sclerotherapy vs N-butyl-2-cyanoacrylate Injection

Conditions

  • Bleeding Esophageal Varices

Interventions

  • Injection SclerotherapyDrug

    5% ethanolamine oleate group

  • N-butyl-2-cyanoacrylateDrug

    N-butyl-2-cyanoacrylate injection group

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with controlled bleedingTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sherief Abd-Elsalam

    Tanta, Egypt

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.